We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Apply for a dermatological product to be considered by the Advisory Committee on Borderline Substances (ACBS).
Report of the Isotretinoin Implementation Advisory Expert Working Group regarding recommendations to strengthen the safe use of isotretinoin, the acne medicine commonly known by brand names Roaccutane and Reticutan.
A retrospective hospital-based, cross-sectional study carried out between 2016 to 2017
Membership and minutes for the Commission on Human Medicines (CHM) and its expert advisory groups (EAGs).
Dr Sue Paterson - FSA Board Member Dr Sue Paterson is a RCVS and European Board-Certified Veterinary Dermatologist. She is an elected Fellow of the RCVS for her contributions to clinical practice in the field of Veterinary Dermatology. She is...
Safety leaflet on topical corticosteroids and withdrawal reactions to help patients and their carers to use these medicines safely.
Information and advice on submitting a dermatological product to the Advisory Committee for Borderline Substances (ACBS).
The Commission on Human Medicines (CHM) has endorsed changes to isotretinoin prescribing guidance. In addition, CHM is seeking further information from dermatology services who prescribe isotretinoin to inform any future changes to current risk minimisation measures.
The updated safety measures will strengthen the MHRA’s ability to monitor safe prescribing while supporting patient access to treatment across all age groups.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).